Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
A full bilingual EN/IT report for WordPress Custom HTML on Draganfly’s current setup, product stack, defense traction, financial reality, dilution profile, scenario map, and the catalysts that matter after the company’s early-2026 funding reset.
Teva entered 2026 with a more credible transformation story than it had just a few years ago. The company reported 2025 revenue of $17.3 billion, up 4% year over year, marking its third consecutive year of growth. That matters because Teva is still carrying the legacy of a global generics business, but the mix is gradually shifting toward innovative medicines, biosimilars, and pipeline assets that management believes can support more durable long-term growth.
Travere Therapeutics did not just clear another FDA box on April 13, 2026. It materially changed the shape of its equity story. FILSPARI, already commercial in IgA nephropathy, now has a second FDA-approved kidney disease indication: reduction of proteinuria in adults and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis, or FSGS, without nephrotic syndrome. That is a narrower label than the most aggressive bulls had once hoped for, but it is still a real commercial approval, not a consolation prize, and it makes FILSPARI the first and only FDA-approved medicine for FSGS.
Hoth added another mechanistic layer to its HT-VA obesity / fatty-liver narrative today, with gene-level data showing reduced Srebf1 and increased Pparα in a VA / Emory CRADA model. That strengthens the scientific story, but it does not remove the core market question: can HOTH turn early preclinical promise and encouraging HT-001 oncology-supportive data into a financed, executable development path without crushing dilution?
From edge-AI pitch to real program conversion: what today’s autonomous-energy-node order says about OSS, how the business changed after the Bressner divestiture, and what still has to go right before this can be treated as a durable public-market winner.
Momentus is still one of the most binary small-cap space stories on the board, but after the last two weeks it is harder to dismiss the company as a pure concept trade. The central reason is not a promotional headline. It is sequence. For a company like MNTS, sequence is everything.
Static Finviz chart at the top. Referral applies only if a reader clicks through. NASDAQ: ONDS Defense · Counter-UAS · ISR · Robotics Updated April 13, 2026 Ondas (ONDS) Deep Dive April 2026 From a narrow drone narrative to a…
Allogene Therapeutics has spent years trying to prove that allogeneic, off-the-shelf CAR-T can become something more than a clever scientific pitch. Today’s ALPHA3 interim futility analysis does not finish that argument, but it materially changes the tone of it.
Daraxonrasib just turned a long-building RAS story into a frontline market conversation. The key question is no longer whether Revolution Medicines has a serious pancreatic program. The question now is how large the platform can become, how quickly the company can convert today’s Phase 3 win into approvals, and how much upside still remains after a violent breakout.
Two biotech names, two very different clinical stories, one synchronized release window. IDEAYA and Spyre are both scheduled to report clinically meaningful updates on Monday, April 13, 2026 at 8:00 a.m. ET, creating an unusually clean side-by-side setup for traders watching biotech volatility, narrative rotation, and cross-flow behavior before the actual readouts hit.
AMC is showing genuine operating improvement, but the common stock is still a highly leveraged instrument sitting underneath a very heavy capital structure.
The tone around PLUG has improved because the company finally delivered concrete signs of stabilization: positive Q4 gross profit, lower cash burn, a clearer execution roadmap, a new CEO, a signed strategic asset sale, and a fresh commercial win in electrolyzers. The key question now is no longer just survival. It is whether improving liquidity can translate into sustainable industrial execution.
A long-form look at how USA Rare Earth is trying to build an integrated non-China rare earth chain across Texas, Oklahoma, the U.K. and France, why the story now matters far beyond mining, and where the real upside and real execution risk sit today.
OPTT is no longer just the old “wave energy” micro-cap many traders remember. The company is trying to reposition itself as a maritime domain awareness and autonomous ocean systems story, with PowerBuoys, WAM-V platforms, Merrows software, defense-adjacent deployments, and a growing pipeline. The opportunity is obvious. The problem is obvious too: the revenue line is still tiny, the cash burn remains heavy, and the balance sheet still leans on dilution and convertible financing.
TLX101-Px accepted by FDA; PDUFA goal date set for September 11, 2026
The clearest near-term regulatory focal point is now TLX101-Px, Telix’s brain cancer imaging candidate for recurrent or progressive glioma. Management has also kept a H1 2026 target for the TLX250-Px / Zircaix BLA resubmission after working through the post-CRL comparability package.
Cingulate is one of those micro-cap biotech stories where the entire equity case has compressed into a narrow window: one lead ADHD asset, one PDUFA date, a visible commercialization build-out, and a very real dilution overhang.
There are trading phrases that survive because they are useful, and there are trading phrases that survive because they are easy to repeat. “The trend is your friend” belongs to both categories. It is useful, but only when treated as a probabilistic framework rather than a religious commandment. Used well, it keeps a trader aligned with momentum, liquidity, and market psychology. Used badly, it turns into a license to chase, overstay, and confuse a mature move with a fresh opportunity.
There are days when the future feels distant, theoretical, something that belongs to policy papers and conference panels. Then there are days when the future stops waiting politely and arrives all at once. April 11, 2026 feels like one of those days. The geopolitical map is unstable, supply chains are once again hostage to geography, financial markets are discovering that volatility is not a passing phase, and the labor market is beginning to absorb the first serious psychological shock from artificial intelligence.
A broad and detailed market recap of the week just ended, plus a forward-looking framework for the next one, with focus on inflation spillover, oil structure, U.S.-Iran diplomacy, bank earnings, producer prices and the increasingly important gap between a stabilizing tape and a still-strained real economy.
Voyager Technologies is one of the more interesting space-defense names because it is not a clean, single-theme stock. It is not just a commercial space dream. It is not just a defense contractor. It is not just a speculative “future station” vehicle either. It is a hybrid company where a real operating business in defense and mission services sits next to a very large long-duration bet on the future commercial low-Earth-orbit economy. That mix is what makes VOYG potentially powerful, but it is also exactly what makes it difficult to value.